Industry

Breakthrough Technologies Institutionalize Evidence-Based Decisions for HTM and Supply Chain Leaders CLEVELAND–(BUSINESS WIRE)–PartsSource, the leading online marketplace for medical equipment maintenance parts and services, unveils significant expansions to PartsSource Pro®, the company’s flagship solution and industry’s first and only clinical resource management platform. Visual Formulary Controls and the Supply Chain Risk Monitor will be leveraged … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Gastrointestinal Devices Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global gastrointestinal devices market is expected to grow from $9.35 billion in 2021 to $10.05 billion in 2022 at a compound annual growth rate (CAGR) of 7.5%. The market is expected to grow to $12.72 billion in 2026 at … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global lateral flow immunoassay (lfia) based rapid test market is expected to grow from $6.08 billion in 2021 to $6.66 billion in 2022 at a compound annual growth rate (CAGR) of 9.4%. The market … [Read more…]

HOUSTON–(BUSINESS WIRE)–U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services (the “Company”), today announced that Chris Reading, Chief Executive Officer, and Carey Hendrickson, Chief Financial Officer, will participate in the Jefferies Healthcare Conference on Wednesday, June 8, 2022. The presentation will cover an … [Read more…]

CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its comprehensive genomic profiling offerings with xF+, a new non-invasive, liquid biopsy panel of 523 genes, focused on pathogenic mutations in cell-free DNA (cfDNA). The test will originally be available on a limited basis alongside xF, Tempus’ 105-gene liquid biopsy … [Read more…]

WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–LTC Properties Inc. (NYSE: LTC), a real estate investment trust that invests in seniors housing and health care properties, today announced that senior management will participate in the NAREIT REITWeek 2022 Investor Conference on Tuesday, June 7 through Thursday June 9, 2022 in New York. The Company’s presentation package will be available … [Read more…]

Findings Published in Health Affairs Forefront Precedent-setting policies to restrict access to accelerated approval drugs do not reduce health care spending but rather harm America’s most vulnerable patients WASHINGTON–(BUSINESS WIRE)–#FacesofAcceleratedApproval–The Partnership to Fight Chronic Disease (PFCD) today released, “Quantifying Impact of Accelerated Approval Drugs on Medicaid Spending: An Update through 2020 and State-Level Analysis,” an … [Read more…]

New Study Uses Medidata Acorn AI solutions to Analyze More than 500 Patients Across Multiple Clinical Study Cohorts NEW YORK–(BUSINESS WIRE)–#ASCO22—Medidata, a Dassault Systèmes company, presented new research on predicting cytokine release syndrome (CRS) resulting from longitudinal CAR T-cell therapy (CAR T) at the American Society for Clinical Oncology (ASCO) Annual Meeting being held June … [Read more…]

Largest Gulf South Health System Will Offer GRAIL’s Galleri® Multi-Cancer Early Detection Test to Patients at Risk for Cancer Multi-Cancer Early Detection Health Equity Demonstration Three-Year Program Aims to Improve Cancer Outcomes Among Underserved Populations and Develop Best Practices for Deployment of Innovative Technologies in Community Settings Ochsner Health to Begin Enrolling Participants in GRAIL’s … [Read more…]

Data Highlighted in Poster Presentation at the National Lipid Association Scientific Sessions SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#KnowFH–The Family Heart Foundation, a leading research and advocacy organization, completed an analysis of its large U.S. Family Heart DatabaseTM demonstrating that lipoprotein(a) – also referred to as Lp(a) — is rarely assessed, despite it being a common, independent risk factor … [Read more…]